SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, today announced an upcoming poster ...
Cyclin D1 is overexpressed in certain solid tumors and hematologic malignancies. In these cancers, the cyclin D1/CDK4 complex drives cell proliferation by binding to the tumor suppressor ...
Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on ...
Circle Internet Group Inc (NASDAQ:CRCL) released its Q3 2025 earnings presentation on November 12, showcasing strong financial performance and significant growth across its stablecoin network. Despite ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a pre-clinical stage company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, will ...
Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an upcoming poster presentation highlighting the ...
SAN FRANCISCO, September 25, 2025--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results